These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33521702)

  • 1. Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity.
    Sheppard HE; Dall'Agnese A; Park WD; Shamim MH; Dubrulle J; Johnson HL; Stossi F; Cogswell P; Sommer J; Levy J; Sharifnia T; Wawer MJ; Nabet B; Gray NS; Clemons PA; Schreiber SL; Workman P; Young RA; Lin CY
    Cell Rep Med; 2021 Jan; 2(1):100188. PubMed ID: 33521702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule targeting of brachyury transcription factor addiction in chordoma.
    Sharifnia T; Wawer MJ; Chen T; Huang QY; Weir BA; Sizemore A; Lawlor MA; Goodale A; Cowley GS; Vazquez F; Ott CJ; Francis JM; Sassi S; Cogswell P; Sheppard HE; Zhang T; Gray NS; Clarke PA; Blagg J; Workman P; Sommer J; Hornicek F; Root DE; Hahn WC; Bradner JE; Wong KK; Clemons PA; Lin CY; Kotz JD; Schreiber SL
    Nat Med; 2019 Feb; 25(2):292-300. PubMed ID: 30664779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
    Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
    J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.
    Shalaby AA; Presneau N; Idowu BD; Thompson L; Briggs TR; Tirabosco R; Diss TC; Flanagan AM
    Mod Pathol; 2009 Aug; 22(8):996-1005. PubMed ID: 19407855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.
    Hsu W; Mohyeldin A; Shah SR; ap Rhys CM; Johnson LF; Sedora-Roman NI; Kosztowski TA; Awad OA; McCarthy EF; Loeb DM; Wolinsky JP; Gokaslan ZL; Quiñones-Hinojosa A
    J Neurosurg; 2011 Oct; 115(4):760-9. PubMed ID: 21699479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death.
    Cottone L; Cribbs AP; Khandelwal G; Wells G; Ligammari L; Philpott M; Tumber A; Lombard P; Hookway ES; Szommer T; Johansson C; Brennan PE; Pillay N; Jenner RG; Oppermann U; Flanagan AM
    Cancer Res; 2020 Oct; 80(20):4540-4551. PubMed ID: 32855205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases.
    Jambhekar NA; Rekhi B; Thorat K; Dikshit R; Agrawal M; Puri A
    Arch Pathol Lab Med; 2010 Aug; 134(8):1181-7. PubMed ID: 20670140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From notochord formation to hereditary chordoma: the many roles of Brachyury.
    Nibu Y; José-Edwards DS; Di Gregorio A
    Biomed Res Int; 2013; 2013():826435. PubMed ID: 23662285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.
    Hu Y; Mintz A; Shah SR; Quinones-Hinojosa A; Hsu W
    Carcinogenesis; 2014 Jul; 35(7):1491-9. PubMed ID: 24445144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.
    Nelson AC; Pillay N; Henderson S; Presneau N; Tirabosco R; Halai D; Berisha F; Flicek P; Stemple DL; Stern CD; Wardle FC; Flanagan AM
    J Pathol; 2012 Nov; 228(3):274-85. PubMed ID: 22847733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival.
    Bettegowda C; Yip S; Lo SL; Fisher CG; Boriani S; Rhines LD; Wang JY; Lazary A; Gambarotti M; Wang WL; Luzzati A; Dekutoski MB; Bilsky MH; Chou D; Fehlings MG; McCarthy EF; Quraishi NA; Reynolds JJ; Sciubba DM; Williams RP; Wolinsky JP; Zadnik PL; Zhang M; Germscheid NM; Kalampoki V; Varga PP; Gokaslan ZL;
    Neuro Oncol; 2017 Mar; 19(3):405-413. PubMed ID: 27663388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study.
    Presneau N; Shalaby A; Ye H; Pillay N; Halai D; Idowu B; Tirabosco R; Whitwell D; Jacques TS; Kindblom LG; Brüderlein S; Möller P; Leithner A; Liegl B; Amary FM; Athanasou NN; Hogendoorn PC; Mertens F; Szuhai K; Flanagan AM
    J Pathol; 2011 Feb; 223(3):327-35. PubMed ID: 21171078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.
    Yamaguchi T; Imada H; Iida S; Szuhai K
    Surg Pathol Clin; 2017 Sep; 10(3):637-656. PubMed ID: 28797506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3.
    Shen J; Li CD; Yang HL; Lu J; Zou TM; Wang DL; Deng M
    J Clin Neurosci; 2011 Jan; 18(1):96-9. PubMed ID: 20855213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poorly differentiated extra-axial extraskeletal chordoma diagnosed by methylation profiling: case report and analysis of brachyury expression in SWI/SNF-deficient tumors.
    Klubíčková N; Michal M; Kinkor Z; Soukup J; Ryška A; Brtková J; Lutonský M; Hájková V; Ptáková N; Michal M; Farkas M; Švajdler M
    Virchows Arch; 2024 Apr; 484(4):621-627. PubMed ID: 37594643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
    Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
    Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposome-Protamine-DNA Nanoparticle-Mediated Delivery of Short Hairpin RNA Targeting Brachyury Inhibits Chordoma Cell Growth.
    Hu Y; Singh R; Deng Z; Mintz A; Hsu W
    J Biomed Nanotechnol; 2016 Oct; 12(10):1952-61. PubMed ID: 29360338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas.
    Vujovic S; Henderson S; Presneau N; Odell E; Jacques TS; Tirabosco R; Boshoff C; Flanagan AM
    J Pathol; 2006 Jun; 209(2):157-65. PubMed ID: 16538613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.
    Zhang L; Guo S; Schwab JH; Nielsen GP; Choy E; Ye S; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    PLoS One; 2013; 8(9):e75851. PubMed ID: 24086644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
    Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
    J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.